Cited by 223Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementHealth Promotion and Cardiovascular Prevention

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.

9. Cardiovascular Disease and Risk Management

American Diabetes Association·2017·Diabetes Care

DOI 10.2337/dc17-s012

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.2337/dc17-s012

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
(2009) · The Lancet · doi:10.1016/s0140-6736(09)60503-1 · Cited by 3,675
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
(2000) · The Lancet · doi:10.1016/s0140-6736(99)12323-7 · Cited by 3,179
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Diabetes in Older Adults
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,151
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Long term mortality of mothers and fathers after pre-eclampsia: population based cohort studyPre-eclampsia and cardiovascular disease later in life: who is at risk?
Irgens, H. U., Roberts, J. M., Reisæter, L., Irgens, L. M., & Lie, R. T. (2001) · BMJ · doi:10.1136/bmj.323.7323.1213 · Cited by 1,040
Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study
Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G., & Mancia, G. (2005) · Circulation · doi:10.1161/01.cir.0000160923.04524.5b · Cited by 1,009
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
(2008) · The Lancet · doi:10.1016/s0140-6736(08)61242-8 · Cited by 1,000
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM
Tatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 843
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809
Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects
Wackers, F. J. T., Young, L. H., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Heller, G. V., Filipchuk, N., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1954 · Cited by 791
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., & Steyn, D. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub3 · Cited by 705
Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Prognostic value of coronary artery calcium screening in subjects with and without diabetes
Raggi, P., Shaw, L. J., Berman, D. S., & Callister, T. Q. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.09.068 · Cited by 608
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Type 1 Diabetes Mellitus and Cardiovascular Disease
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 516
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy
Anand, D. V., Lim, E., Hopkins, D., Corder, R., Shaw, L. J., Sharp, P., Lipkin, D., & Lahiri, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi808 · Cited by 392
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis
Huxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383
Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Whelton, P. K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1401 · Cited by 290
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M. P., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W. F., & Kirkman, M. S. (2010) · Diabetes Care · doi:10.2337/dc10-0555 · Cited by 269
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study
Elkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., & for the PREDICT Study Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn279 · Cited by 261
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259
Screening for coronary artery disease in patients with diabetes
Bax, J. J., Young, L. H., Frye, R. L., Bonow, R. O., Steinberg, H. O., & Barrett, E. J. (2007) · Diabetes Care · doi:10.2337/dc07-9927 · Cited by 251
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus
Scognamiglio, R., Negut, C., Ramondo, A., Tiengo, A., & Avogaro, A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.008 · Cited by 249
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.046 · Cited by 244
Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54
Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Influence of Time of Day of Blood Pressure–Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · Diabetes Care · doi:10.2337/dc11-0297 · Cited by 213
Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204
Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183
Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 163
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Blood pressure targets for hypertension in people with diabetes mellitus
Arguedas, J. A., Leiva, V., & Wright, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008277.pub2 · Cited by 151
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., & Ge, J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.029 · Cited by 150
Sex Differences in Diabetes and Risk of Incident Coronary Artery Disease in Healthy Young and Middle-Aged Adults
Kalyani, R. R., Lazo, M., Ouyang, P., Turkbey, E. B., Chevalier, K., Brancati, F. L., Becker, D. M., & Vaidya, D. M. (2013) · Diabetes Care · doi:10.2337/dc13-1755 · Cited by 142
Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study
Wackers, F. J. T., Chyun, D. A., Young, L. H., Heller, G. V., Iskandrian, A. E., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Filipchuk, N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-1250 · Cited by 137
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
McBrien, K., Rabi, D. M., Campbell, N., Barnieh, L., Clement, F., Hemmelgarn, B. R., Tonelli, M., Leiter, L. A., Klarenbach, S. W., & Manns, B. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3147 · Cited by 129
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Schrier, R. W., Estacio, R. O., Mehler, P. S., & Hiatt, W. R. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0559 · Cited by 128
Is "Isolated Home" Hypertension as Opposed to "Isolated Office" Hypertension a Sign of Greater Cardiovascular Risk?
Bobrie, G., Genès, N., Vaur, L., Clerson, P., Vaisse, B., Mallion, J.-M., & Chatellier, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2205 · Cited by 117
Evening versus morning dosing regimen drug therapy for hypertension
Zhao, P., Xu, P., Wan, C., & Wang, Z. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004184.pub2 · Cited by 113
Statins for primary prevention of cardiovascular disease
Majeed, A. (2014) · BMJ · doi:10.1136/bmj.g3491 · Cited by 103
Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial
Anderson, R. J., Bahn, G. D., Moritz, T. E., Kaufman, D., Abraira, C., Duckworth, W., & for the VADT Study Group (2011) · Diabetes Care · doi:10.2337/dc10-1420 · Cited by 93
Prognostic Value of Coronary Computed Tomographic Angiography in Diabetic Patients Without Known Coronary Artery Disease
Hadamitzky, M., Hein, F., Meyer, T., Bischoff, B., Martinoff, S., Schömig, A., & Hausleiter, J. (2010) · Diabetes Care · doi:10.2337/dc09-2104 · Cited by 90
Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Kezerashvili, A., Marzo, K. P., & Leon, J. D. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215764 · Cited by 81
Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes
Bethel, M. A., Harrison, P., Sourij, H., Sun, Y., Tucker, L., Kennedy, I., White, S., Hill, L., Oulhaj, A., Coleman, R. L., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.12828 · Cited by 61
Assessment of Subclinical Coronary Atherosclerosis in Asymptomatic Patients With Type 2 Diabetes Mellitus With Single Photon Emission Computed Tomography and Coronary Computed Tomography Angiography
Choi, E.-K., Chun, E. J., Choi, S.-I., Chang, S.-A., Choi, S.-H., Lim, S., Rivera, J. J., Nasir, K., Blumenthal, R. S., Jang, H.-C., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.026 · Cited by 57
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., Cavalca, V., Ciminello, A., Habib, A., Squellerio, I., et al. (2016) · Diabetes · doi:10.2337/db15-0936 · Cited by 53
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study
Meek, C., Wierzbicki, A. S., Jewkes, C., Twomey, P. J., Crook, M. A., Jones, A., & Viljoen, A. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657302 · Cited by 52
Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease
Larsen, S. B., Grove, E. L., Neergaard‐Petersen, S., Würtz, M., Hvas, A., & Kristensen, S. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126767 · Cited by 51
Evening‐ versus morning‐dosing‐regimen drug therapy for hypertension
(2011) · Prescriber · doi:10.1002/psb.830 · Cited by 48
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease
Mora, S., Ames, J. M., & Manson, J. E. (2016) · JAMA · doi:10.1001/jama.2016.8362 · Cited by 41
Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes—Network meta-analysis of randomized trials
Remonti, L. R., Dias, S., Leitão, C. B., Kramer, C. K., Klassmann, L. P., Welton, N. J., Ades, A. E., & Gross, J. L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.020 · Cited by 37
Use of diuretics during pregnancy.
Al-Balas, M., Bozzo, P., & Einarson, A. (2009) · PubMed Central · Cited by 35
Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus
Dimitriu‐Leen, A. C., Scholte, A. J. H. A., van Rosendael, A. R., van den Hoogen, I. J., Kharagjitsingh, A. V., Wolterbeek, R., Knuuti, J. M., Kroft, L. J. M., Delgado, V., Jukema, J. W., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.12.023 · Cited by 25
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5

Flagged first, then by citations

Research works printed but not linked: 1

American College of Obstetricians and Gynecologists, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122

Sorted by citations

Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Diabetes and lipid metabolism
Athyros, V. G., Doumas, M. N., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0014-8 · Cited by 384
Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity
Fisher, D. P., Johnson, E., Haneuse, S., Arterburn, D., Coleman, K. J., O’Connor, P. J., O’Brien, R., Bogart, A., Theis, M. K., Anau, J., et al. (2018) · JAMA · doi:10.1001/jama.2018.14619 · Cited by 305
Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease
Rippe, J. M. (2018) · American Journal of Lifestyle Medicine · doi:10.1177/1559827618812395 · Cited by 362
Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245

See all 223

Authors: American Diabetes Association
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2016-12-12
Volume: 40
Issue: Supplement_1
Pages: S75-S87
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc17-s012
OpenAlex: W4254397911
Semantic Scholar: ac7f21cc7fc32a6a809a86ed7a1cbf0b7423a650
Cited by: 223
References: 119
Citations by year: 2026: 3 · 2025: 5 · 2024: 7 · 2023: 13 · 2022: 19 · 2021: 16 · 2020: 15 · 2019: 29 · 2018: 47 · 2017: 63 · 2016: 6
FWCI: 7.05
Type: journal article
Language: en
Open access: closed
Licence: www.diabetesjournals.org/content/license (vor, 3 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords: cardiovascular disease, cardiovascular risk management, diabetes mellitus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

9. Cardiovascular Disease and Risk Management

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks